Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

IFTIKHAR HUSSAIN

Allopathic & Osteopathic Physicians Internal Medicine Allergy & Immunology

NPI
1205854015
CMS profile
191178
Location
TULSA, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$27,876.61

134 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

IFTIKHAR HUSSAIN

NPI 1205854015 · CMS profile ID 191178

Allopathic & Osteopathic Physicians / Internal Medicine / Allergy & Immunology

TULSA, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1205854015?year=2020&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
IFTIKHAR HUSSAIN, NPI 1205854015, CMS profile ID 191178. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1205854015?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). IFTIKHAR HUSSAIN, NPI 1205854015, CMS profile ID 191178. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1205854015?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
IFTIKHAR HUSSAIN, NPI 1205854015, CMS profile ID 191178, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1205854015?year=2020&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

134 matching records · $27,876.61 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 134 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–134 of 134.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Grifols USA, LLC $10.2602/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750407019 CMS
Janssen Biotech, Inc. $5.5902/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719173741 CMS
Novartis Pharmaceuticals Corporation $17.8602/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725820385 CMS
PFIZER INC. $99.9502/22/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743808999 CMS
PFIZER INC. $587.4402/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743809001 CMS
PFIZER INC. $418.0002/22/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743809003 CMS
CSL Behring $17.0302/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728950839 CMS
kaleo, Inc. $11.7802/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 733174529 CMS
PFIZER INC. $10.6802/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743525165 CMS
GlaxoSmithKline, LLC. $15.8001/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738580267 CMS
Allergan, Inc. $12.6401/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723726707 CMS
Adare Pharmaceuticals, Inc. $60.7001/23/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750444425 CMS
Adare Pharmaceuticals, Inc. $100.1401/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750444428 CMS
AstraZeneca Pharmaceuticals LP $97.2001/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736297861 CMS
CSL Behring $3,995.0001/22/2020 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728950867 CMS
CSL Behring $40.0001/22/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728950869 CMS
CSL Behring $20.7001/22/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728950871 CMS
CSL Behring $11.7301/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728950873 CMS
CSL Behring $6.7901/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728950875 CMS
CSL Behring $6.0701/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728950877 CMS
Genentech USA, Inc. $20.6801/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743022249 CMS
CSL Behring $698.1901/15/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728950859 CMS
CSL Behring $614.2801/15/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728950861 CMS
CSL Behring $312.3601/15/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728950863 CMS
CSL Behring $96.0701/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728950865 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.3501/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747206239 CMS
Adare Pharmaceuticals, Inc. $219.5201/12/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750444375 CMS
Adare Pharmaceuticals, Inc. $219.5201/12/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750444377 CMS
Adare Pharmaceuticals, Inc. $757.2401/11/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750444373 CMS
Adare Pharmaceuticals, Inc. $170.4901/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750444423 CMS
Adare Pharmaceuticals, Inc. $152.0201/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750444381 CMS
AstraZeneca Pharmaceuticals LP $13.2901/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736093603 CMS
Daiichi Sankyo Inc. $20.0201/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739476791 CMS
PFIZER INC. $650.0001/02/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743518567 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $73,169.30 238
PY2020 $27,876.61 134
PY2021 $10,926.50 129
PY2022 $21,924.28 160
PY2023 $6,072.07 163
PY2024 $37,709.04 198
PY2025 $12,718.83 171

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $629,788.33 134
PY2024 Recipient $2,905.87 20
PY2024 Principal investigator $628,299.41 288
PY2023 Recipient $4,519.45 21
PY2023 Principal investigator $635,851.56 145
PY2022 Recipient $1,420.86 3
PY2022 Principal investigator $809,681.00 155
PY2021 Recipient $4,914.51 13
PY2021 Principal investigator $1,135,913.89 172
PY2020 Recipient $35,787.20 37
PY2020 Principal investigator $1,489,586.31 235
PY2019 Recipient $8,763.38 14
PY2019 Principal investigator $1,610,045.70 236

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

134 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $25,650.00 12/23/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192132293
Principal investigator 1 GlaxoSmithKline, LLC. $2,397.60 12/19/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192132286
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,091.60 12/19/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223289944
Principal investigator 1 PFIZER INC. $5,553.91 12/17/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research Institute PC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228816142
Principal investigator 1 PFIZER INC. $2,712.83 12/16/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research Institute PC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228817027
Principal investigator 1 PFIZER INC. $4,732.09 12/11/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research Institute PC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228817065
Principal investigator 1 SANOFI US SERVICES INC. $3,440.80 12/08/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research I Institute PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226086522
Principal investigator 1 ABBVIE INC. $4,418.00 12/04/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202527060
Principal investigator 1 PFIZER INC. $5,552.37 11/26/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research Institute PC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228818303
Principal investigator 1 GlaxoSmithKline, LLC. $15,547.00 11/25/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192183414
Principal investigator 1 GlaxoSmithKline, LLC. $15,137.10 11/25/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192183457
Principal investigator 1 PFIZER INC. $3,476.70 11/18/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research Institute PC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228818309
Principal investigator 1 Kedrion Biopharma, Inc. $1,648.65 11/17/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
KEDBEN60-0D1OMG No dispute reported 06/30/2026 1208555035
Principal investigator 1 SANOFI US SERVICES INC. $7,809.60 11/10/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research I Institute PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226086607
Principal investigator 1 PFIZER INC. $4,877.62 10/31/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research Institute PC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228826124
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $954.90 10/23/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223287373
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $429.00 10/20/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184251518
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $429.00 10/20/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184251520
Principal investigator 1 GlaxoSmithKline, LLC. $15,381.00 10/17/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192183422
Principal investigator 1 GlaxoSmithKline, LLC. $853.20 10/17/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192183445
Principal investigator 1 ABBVIE INC. $1,809.70 10/09/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202514203
Principal investigator 1 SANOFI US SERVICES INC. $2,801.80 10/06/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research I Institute PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226086603
Principal investigator 1 GlaxoSmithKline, LLC. $3,244.41 10/02/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192182046
Principal investigator 1 GlaxoSmithKline, LLC. $81,836.35 10/02/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192183431
Principal investigator 1 Kedrion Biopharma, Inc. $5,090.91 10/02/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
KEDBEN60-0D1OMG No dispute reported 06/30/2026 1208555033
Principal investigator 1 Novartis Pharmaceuticals Corporation $140.00 10/01/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190304303
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $135.00 10/01/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223286013
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,280.00 09/24/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185550747
Principal investigator 1 PFIZER INC. $2,274.36 09/24/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research Institute PC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228835495
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,809.90 09/23/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223285810
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,200.00 09/19/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185550749
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $954.90 09/18/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223285630
Principal investigator 1 SANOFI US SERVICES INC. $4,659.00 09/15/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research I Institute PC
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226086599
Principal investigator 1 PFIZER INC. $2,226.08 09/10/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research Institute PC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228835490
Principal investigator 1 PFIZER INC. $2,112.08 09/09/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research Institute PC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228835538
Principal investigator 1 GlaxoSmithKline, LLC. $1,184.00 09/08/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192183435
Principal investigator 1 Optinose US, Inc. $6,500.00 09/05/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research Institute, P.C.
A 12-Week Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 mcg of OPN-375 Twice a Day (BID) in Adolescent Subjects With Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1163251991
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,299.50 09/04/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223285097
Principal investigator 1 ABBVIE INC. $354.40 09/03/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202507777
Principal investigator 1 GlaxoSmithKline, LLC. $2,228.40 09/03/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192182042
Principal investigator 1 SANOFI US SERVICES INC. $2,792.40 09/03/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research I Institute PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226086595
Principal investigator 1 ABBVIE INC. $4,055.86 08/25/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1202505699
Principal investigator 1 Kedrion Biopharma, Inc. $2,310.87 08/25/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
KEDBEN60-0D1OMG No dispute reported 06/30/2026 1208554933
Principal investigator 1 SANOFI US SERVICES INC. $10,994.40 08/18/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research I Institute PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226086589
Principal investigator 1 ABBVIE INC. $1,978.50 08/14/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1202504807
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,088.90 08/14/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223284243
Principal investigator 1 GlaxoSmithKline, LLC. $9,930.00 08/13/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192183409
Principal investigator 1 PFIZER INC. $4,783.66 08/09/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research Institute PC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228843507
Principal investigator 1 ABBVIE INC. $408.90 08/05/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202501826
Principal investigator 1 GlaxoSmithKline, LLC. $4,845.60 08/04/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192183426
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $175.00 08/01/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223283309
Principal investigator 1 Kedrion Biopharma, Inc. $2,310.87 07/28/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
KEDBEN60-0D1OMG No dispute reported 06/30/2026 1208554935
Principal investigator 1 GlaxoSmithKline, LLC. $3,310.00 07/23/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192183405
Principal investigator 1 GlaxoSmithKline, LLC. $4,971.54 07/23/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192183441
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,088.90 07/22/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223282894
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $429.00 07/18/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184217497
Principal investigator 1 PFIZER INC. $2,041.20 07/16/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research Institute PC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228848219
Principal investigator 1 SANOFI US SERVICES INC. $6,975.85 07/14/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research I Institute PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226086585
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,088.90 07/04/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223282224
Principal investigator 1 ABBVIE INC. $302.60 07/02/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202495611
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $135.00 07/01/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223281928
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $135.00 07/01/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223281932
Principal investigator 1 PFIZER INC. $21,289.29 06/26/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research Institute PC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228851929
Principal investigator 1 PFIZER INC. $1,500.00 06/26/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research Institute PC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228851936
Principal investigator 1 GlaxoSmithKline, LLC. $12,675.00 06/20/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192183401
Principal investigator 1 GlaxoSmithKline, LLC. $3,212.10 06/20/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192183449
Principal investigator 1 Eli Lilly and Company $3,000.00 06/16/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INST PC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1187893458
Principal investigator 1 Kedrion Biopharma, Inc. $2,780.04 06/16/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
KEDBEN60-0D1OMG No dispute reported 06/30/2026 1208555001
Principal investigator 1 SANOFI US SERVICES INC. $9,442.00 06/16/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research I Institute PC
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226086576
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,088.90 06/12/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223281130
Principal investigator 1 SANOFI US SERVICES INC. $9,446.54 06/09/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research I Institute PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226086581
Principal investigator 1 Eli Lilly and Company $5,870.10 06/05/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INST PC
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187893456
Principal investigator 1 ABBVIE INC. $971.30 06/03/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202489287
Principal investigator 1 Novartis Pharmaceuticals Corporation $27,156.48 06/01/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190304305
Principal investigator 1 PFIZER INC. $2,695.00 05/30/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research Institute PC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07264660 IN ADULT PARTICIPANTS WITH MODERATESEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228857728
Principal investigator 1 PFIZER INC. $25,460.40 05/29/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research Institute PC
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228855701
Principal investigator 1 SANOFI US SERVICES INC. $1,376.95 05/27/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research I Institute PC
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) No dispute reported 06/30/2026 1226086567
Principal investigator 1 SANOFI US SERVICES INC. $10,587.00 05/27/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research I Institute PC
CSU - Patient study in children aged 2 years to < 12 years No dispute reported 06/30/2026 1226086571
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,088.90 05/22/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223280140
Principal investigator 1 GlaxoSmithKline, LLC. $3,527.10 05/21/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192183396
Principal investigator 1 Kedrion Biopharma, Inc. $4,731.72 05/19/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
KEDBEN60-0D1OMG No dispute reported 06/30/2026 1208555003
Principal investigator 1 ABBVIE INC. $1,770.70 05/06/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202481527
Principal investigator 1 ABBVIE INC. $97.50 05/06/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202481531
Principal investigator 1 SANOFI US SERVICES INC. $8,868.43 05/05/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research I Institute PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226086563
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $175.00 05/01/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223278726
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,088.90 04/28/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223278648
Principal investigator 1 GlaxoSmithKline, LLC. $7,036.20 04/23/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192183418
Principal investigator 1 Incyte Corporation $500.00 04/14/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240615703
Principal investigator 1 Incyte Corporation $129.00 04/14/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240615707
Principal investigator 1 Incyte Corporation $36.00 04/14/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240615710
Principal investigator 1 Incyte Corporation $500.00 04/14/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240615714
Principal investigator 1 Incyte Corporation $2,000.70 04/14/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240615721
Principal investigator 1 Incyte Corporation $200.00 04/14/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240615730
Principal investigator 1 Novartis Pharmaceuticals Corporation $16,408.54 04/08/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U No dispute reported 06/30/2026 1190304301
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,222.10 04/08/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223277624
Principal investigator 1 SANOFI US SERVICES INC. $6,066.75 04/07/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research I Institute PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226086555
Principal investigator 1 GlaxoSmithKline, LLC. $250.00 04/04/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP, MUL No dispute reported 06/30/2026 1192182038
Principal investigator 1 ABBVIE INC. $299.00 04/03/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202469217
Principal investigator 1 Incyte Corporation $16.18 04/02/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240615718
Principal investigator 1 Incyte Corporation $22.90 04/02/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240615727
Principal investigator 1 Incyte Corporation $11.52 04/02/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240615732
Principal investigator 1 Incyte Corporation $1.96 04/02/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240615735
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,299.50 03/19/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223276783
Principal investigator 1 SANOFI US SERVICES INC. $6,474.90 03/17/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research I Institute PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226086543
Principal investigator 1 Kedrion Biopharma, Inc. $2,310.87 03/10/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
KEDBEN60-0D1OMG No dispute reported 06/30/2026 1208554971
Principal investigator 1 ABBVIE INC. $1,570.90 03/06/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202457867
Principal investigator 1 SANOFI US SERVICES INC. $2,820.00 03/04/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research I Institute PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226086539
Principal investigator 1 GlaxoSmithKline, LLC. $4,608.00 02/25/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192183454
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,088.90 02/25/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223275513
Principal investigator 1 Incyte Corporation $2,117.70 02/19/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240615687
Principal investigator 1 SANOFI US SERVICES INC. $6,577.58 02/18/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research I Institute PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226086535
Principal investigator 1 Kedrion Biopharma, Inc. $2,897.04 02/10/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
KEDBEN60-0D1OMG No dispute reported 06/30/2026 1208554969
Principal investigator 1 ABBVIE INC. $4,546.00 02/05/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202445041
Principal investigator 1 ABBVIE INC. $2,076.90 02/05/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH
M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) No dispute reported 06/30/2026 1202445043
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,088.90 02/05/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223274765
Principal investigator 1 SANOFI US SERVICES INC. $7,766.10 01/27/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research I Institute PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226086530
Principal investigator 1 GlaxoSmithKline, LLC. $10,768.50 01/24/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192183462
Principal investigator 1 SANOFI US SERVICES INC. $580.00 01/21/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research I Institute PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226086547
Principal investigator 1 Incyte Corporation $1,453.80 01/17/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240615684
Principal investigator 1 Incyte Corporation $1,671.00 01/17/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240615689
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,088.90 01/17/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223274013
Principal investigator 1 ABBVIE INC. $1,617.40 01/15/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202438709
Principal investigator 1 Novartis Pharmaceuticals Corporation $135.48 01/15/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihi No dispute reported 06/30/2026 1190304299
Principal investigator 1 PFIZER INC. $400.00 01/15/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research Institute PC
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1228863639
Principal investigator 1 Kedrion Biopharma, Inc. $4,621.74 01/13/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
KEDBEN60-0D1OMG No dispute reported 06/30/2026 1208554973
Principal investigator 1 Eli Lilly and Company $15,939.90 01/07/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INST PC
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1187893690
Principal investigator 1 Kedrion Biopharma, Inc. $1,227.98 01/07/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
KEDBEN60-0D1OMG No dispute reported 06/30/2026 1208554963
Principal investigator 1 Kedrion Biopharma, Inc. $500.00 01/07/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
KEDBEN60-0D1OMG No dispute reported 06/30/2026 1208554965
Principal investigator 1 Kedrion Biopharma, Inc. $1,606.56 01/07/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
KEDBEN60-0D1OMG No dispute reported 06/30/2026 1208554967
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,088.90 01/07/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE PC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223273641
Principal investigator 1 SANOFI US SERVICES INC. $3,580.00 01/06/2025 Non-covered Recipient Entity
Vital Prospects Clinical Research I Institute PC
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226086558
Principal investigator 1 Incyte Corporation $123.90 01/02/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240615693
Principal investigator 1 Incyte Corporation $66.24 01/02/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE, PC VPCRI
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240615698
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,087.83 01/01/2025 Non-covered Recipient Entity
VITAL PROSPECTS CLINICAL RESEARCH INSTITUTE
A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Adult Participants With Peanut Allergy No dispute reported 06/30/2026 1190304307

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2021 Amount invested $70,000.00 1
PY2021 Value of interest $70,000.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

1 record · PY2021

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2021 Medico CX Inc $70,000.00 $70,000.00 167,865 shares at $0.42 each Physician Covered Recipient No dispute reported 06/30/2026 855029437